Pipeline
| PRODUCT/REGULATORY PATH | THERAPEUTIC AREA | PROGRAM | PRECLINICAL | PHASE I | PHASE II | PHASE III | LAUNCH | EXCLUSIVITY |
|---|---|---|---|---|---|---|---|---|
| 4-AP (Dalfampridine) (505b2) | Cerebellar Ataxias | SLX-100 |  | 2027 | 2034 ODD | |||
| Nerve Injury | SLX-100 |  | 2029 | 2034 US 2036 EU, CA | ||||
| Novel Aminopyridine (505b1) | CIPN | SOL-100 |  | TBD | Pending | |||
| Confidential | SOL-100 |  | TBD | Pending |
For SLX-100, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission
Issued patent protection
- through 2036: 4-Aminopyridine
- through 2038: Confidential